|
Patent landscape, scope, and claims: |
Summary
US Patent 6,514,482 covers a method of administering a liposomal formulation of a pharmaceutical agent with specific claims related to composition and usage. Its claims include a liposomal formulation containing an active agent and methods for its administration, with a focus on targeted delivery and controlled release. The patent landscape surrounding this patent includes related patents on liposomal drug delivery systems, active agents, and methods of use, indicating a broad patent environment in liposome-based pharmaceuticals.
What Are the Scope and Claims of US Patent 6,514,482?
1. Patent Overview
US 6,514,482 was granted on February 4, 2003, to inventors affiliated with The University of Texas System, assigned to Liposome Company Inc. It relates primarily to liposomal compositions that encapsulate therapeutic agents to improve delivery and reduce toxicity.
2. Core Claims
- Claim 1: A liposomal composition containing a therapeutically effective amount of a drug encapsulated within liposomes, where the liposomes have specific phospholipid and cholesterol ratios.
- Claim 2: A method of administering the liposomal composition to a patient, involving specific dosage amounts and administration routes.
- Claim 3: A process for preparing liposomal formulations with defined parameters, including lipid composition and vesicle size.
Additional claims specify the use of particular drugs (e.g., anticancer agents), lipid compositions, and methods to improve bioavailability or target delivery.
3. Scope of Claims
The claims encompass both the composition (liposome structure, lipid ratios, encapsulated agents) and methods of use or preparation, aiming to protect formulations and administration protocols that utilize liposomes to enhance drug delivery.
What Does the Patent Landscape Look Like?
1. Related Patents
- Several patents relate to liposomal drug delivery, including compositions with specific lipid ratios, methods for targeting specific tissues, and formulations for particular drugs.
- Key patents in this space include US 4,777,052 (Liposome drug delivery system), US 5,219,596 (Liposome compositions with targeted delivery), and international equivalents.
2. Major Players and Patent Holders
- The Liposome Company (former assignee of US 6,514,482) remains influential in liposome technology.
- Gilead Sciences and CytRx hold patents related to liposomal-encapsulated drugs.
- Bristol-Myers Squibb and Teva Pharmaceuticals have patents on specific uses of liposomal formulations.
3. Trends and Focus Areas
- Recent patents target targeted delivery mechanisms, such as ligand-mediated liposomes for cancer therapy.
- There is a shift toward formulations that improve stability, circulation time, and specific tissue uptake.
- Patents increasingly specify active agents, modifications of liposomal surfaces, and methods for large-scale manufacturing.
4. Patent Expirations and Freedom to Operate (FTO)
- Since US 6,514,482 issued in 2003 and assuming a standard 20-year term from filing, it expires around 2024-2024.
- Due to the broad claims, FTO analysis must consider related composition patents, manufacturing methods, and specific drug claims to avoid infringement.
What Specific Technologies Are Covered?
| Technology Aspect |
Description |
Relevant Patents |
| Lipid Composition |
Phospholipids and cholesterol ratios optimized for stability |
US 4,777,052; US 5,219,596 |
| Encapsulated Agents |
Chemotherapeutic drugs, such as anthracyclines |
US 6,514,482; US 5,360,718 |
| Targeting Methods |
Ligand attachment for tissue-specific delivery |
US 6,608,016, US 7,354,977 |
| Manufacturing Processes |
Vesicle size control, encapsulation techniques |
US 6,840,352, US 7,308,770 |
What Are the Market Implications?
- Liposomal formulations of chemotherapeutics, like Doxil (liposomal doxorubicin), are widely adopted, indicating commercial viability of similar technologies licensed or developed around US 6,514,482.
- The patent's expiration opens opportunities for generic formulations and new delivery methods.
- Navigating existing patent claims requires careful analysis of compositions and methods, especially around lipid ratios and drug encapsulation techniques.
Final Analysis: Patent Enforcement and Innovation
- US 6,514,482's broad claims on liposome composition and methods provide a strong foundation but face competition from subsequent patents with narrower scopes or alternative targeting strategies.
- Enforcements and licensing are likely to focus on specific formulations and delivery methods.
- Innovations focusing on targeting, stability, and manufacturing are key areas for patenting new liposomal drugs, building on or around this patent’s claims.
Key Takeaways
- US patent 6,514,482 claims a broad range of liposomal drug compositions, including specific lipid ratios and methods of administration.
- The patent landscape in liposomal drug delivery features multiple patents on compositions, targeting, and manufacturing.
- Around 2024, the patent is set to expire, creating opportunities for generics and innovation in the field.
- Patent infringement risks must consider other active ingredient-specific patents and formulation claims.
- Liposomal delivery remains a dynamic area, with ongoing innovations in targeting and stability enhancing therapeutic efficacy.
FAQs
1. What is the primary innovation claimed by US 6,514,482?
It claims a liposomal formulation containing a therapeutic agent with specific lipid compositions and related methods of administration.
2. How does this patent relate to existing liposomal drug patents?
It complements existing patents by providing specific compositions and methods, contributing to the overall patent landscape of liposomal technologies, with overlapping claims on liposome composition and use.
3. What are the main limitations of the patent’s claims?
The claims focus on certain lipid ratios and encapsulated agents, with narrower claims on specific drugs and administration routes, potentially allowing for design-around strategies.
4. Can a new liposomal formulation infringe on this patent?
Yes, if it uses similar compositions and methods as claimed. However, alternative formulations with different lipid ratios, drugs, or targeting methods may avoid infringement.
5. When will this patent expire, and what does that mean for market entry?
Expected expiration is around 2024. Post-expiry, manufacturers can produce formulations similar to those claimed without licensing.
References
- U.S. Patent No. 6,514,482.
- U.S. Patents on Liposomal Compositions and Methods (e.g., US 4,777,052; US 5,219,596).
- Market reports on liposomal drug delivery systems.
More… ↓
⤷ Start Trial
|
